000141400 001__ 141400
000141400 005__ 20240229112524.0
000141400 0247_ $$2doi$$a10.2967/jnumed.118.211086
000141400 0247_ $$2pmid$$apmid:29976697
000141400 0247_ $$2ISSN$$a0022-3123
000141400 0247_ $$2ISSN$$a0097-9058
000141400 0247_ $$2ISSN$$a0161-5505
000141400 0247_ $$2ISSN$$a1535-5667
000141400 0247_ $$2ISSN$$a2159-662X
000141400 0247_ $$2altmetric$$aaltmetric:44680460
000141400 037__ $$aDKFZ-2018-01906
000141400 041__ $$aeng
000141400 082__ $$a610
000141400 1001_ $$0P:(DE-HGF)0$$aKoerber, Stefan A$$b0$$eFirst author
000141400 245__ $$a68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.
000141400 260__ $$aNew York, NY$$bSoc.$$c2019
000141400 3367_ $$2DRIVER$$aarticle
000141400 3367_ $$2DataCite$$aOutput Types/Journal article
000141400 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1635932299_16620
000141400 3367_ $$2BibTeX$$aARTICLE
000141400 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141400 3367_ $$00$$2EndNote$$aJournal Article
000141400 500__ $$avol. 60 no. 2 234-240
000141400 520__ $$aThe present study analyzed the impact of Gallium-68 (68Ga)-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery and 60 presented with recurrent PSA following definitive therapy. Changes in TNM classification of malignant tumors (TNM) stage and radiotherapeutic management after 68Ga-PSMA-11 imaging were compared to results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment naïve patients, a change in TNM stage and radiotheraeutic plan occurred in 26.0% and 44.0% of the cohort respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3% respectively. Conclusion:68Ga-PSMA-11 PET/CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naïve patients as well as in men with recurrent disease or persistent PSA and seems to be very helpful in personalizing radiotherapeutic management to the individual patients' distribution of disease.
000141400 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000141400 588__ $$aDataset connected to CrossRef, PubMed,
000141400 7001_ $$aWill, Leon$$b1
000141400 7001_ $$0P:(DE-HGF)0$$aKratochwil, Clemens$$b2
000141400 7001_ $$0P:(DE-HGF)0$$aHaefner, Matthias F$$b3
000141400 7001_ $$aRathke, Henrik$$b4
000141400 7001_ $$aKremer, Christophe$$b5
000141400 7001_ $$aMerkle, Jonas$$b6
000141400 7001_ $$0P:(DE-HGF)0$$aHerfarth, Klaus$$b7
000141400 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b8
000141400 7001_ $$aChoyke, Peter L$$b9
000141400 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b10
000141400 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b11$$udkfz
000141400 7001_ $$0P:(DE-HGF)0$$aDebus, Juergen$$b12
000141400 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b13$$eLast author$$udkfz
000141400 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.118.211086$$gp. jnumed.118.211086 -$$n2$$p234-240$$tJournal of nuclear medicine$$v60$$x2159-662X$$y2019
000141400 909CO $$ooai:inrepo02.dkfz.de:141400$$pVDB
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000141400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000141400 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000141400 9141_ $$y2019
000141400 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2017
000141400 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141400 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141400 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141400 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141400 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141400 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141400 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141400 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141400 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141400 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141400 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141400 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2017
000141400 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000141400 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x1
000141400 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x2
000141400 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000141400 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x4
000141400 980__ $$ajournal
000141400 980__ $$aVDB
000141400 980__ $$aI:(DE-He78)E050-20160331
000141400 980__ $$aI:(DE-He78)E060-20160331
000141400 980__ $$aI:(DE-He78)E030-20160331
000141400 980__ $$aI:(DE-He78)L101-20160331
000141400 980__ $$aI:(DE-He78)C060-20160331
000141400 980__ $$aUNRESTRICTED